License And Collaboration Agreement, Development Payment

No definition available.

Name:	til_LicenseAndCollaborationAgreementDevelopmentPayment
Namespace Prefix:	til_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License And Collaboration Agreement, Up Front Payment, Additional Accrual

+ References

No definition available.

+ Details

Name:	til_LicenseAndCollaborationAgreementUpFrontPaymentAdditionalAccrual
Namespace Prefix:	til_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License And Collaboration Agreement, Upfront Payment

+ References

No definition available.

+ Details

Name:	til_LicenseAndCollaborationAgreementUpfrontPayment
Namespace Prefix:	til_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License And Development Agreement, Development Cost, Period Cost

+ References

No definition available.

+ Details

Name:	til_LicenseAndDevelopmentAgreementDevelopmentCostPeriodCost
Namespace Prefix:	til_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=til_AxionBioInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=til_CommercialDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=til_LongTermDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=til_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreement with ImmuneOnco (Details) - USD ($) $ in Millions		3 Months Ended			6 Months Ended		12 Months Ended
	Aug. 01, 2024	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024	Apr. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional accrual for prepayment of development costs								$ 5.0
Axion
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment							$ 10.0
Development cost			$ 5.0
Collaboration agreement costs incurred		$ 14.1		$ 0.0	$ 18.4	$ 0.0
Axion \| License Agreement Terms \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Licensing agreement compensation	$ 20.0
Axion \| Commercial, development and regulatory milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional accrual for prepayment of development costs		0.7			0.7
Development payment		$ 10.0			$ 10.0
Axion \| Commercial, development and regulatory milestones \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Licensing agreement compensation	2,100.0
Axion \| Long-Term regulatory milestones \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Licensing agreement compensation	270.0
Axion \| Commercial Milestones \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Licensing agreement compensation	$ 1,800.0